{
  "docId": "019de076-a4b3-719a-94d2-ca29be1b4679",
  "docSlug": "0f14c676100503df3bb87c658cc9d332",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 26,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "Includes medical imaging (SPECT/CT) comparing baseline vs. cold antibody intervention.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-a4b3-719a-94d2-ca29be1b4679/18",
  "deckHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679",
  "deckJsonHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679.json",
  "deckAnchorHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.52,
        "x": 0.03,
        "y": 0.185
      },
      "kind": "image",
      "text": "Comparison of SPECT/CT scans with and without cold antibody",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07b1a247-dc45-41ac-8505-475bcb65aafc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.57,
        "y": 0.35
      },
      "kind": "list",
      "text": "No DLTs, limited to transient Grade 1 or less thrombocytopenia; 2/3 patients showed stable disease; Dose escalated to 25 kBq/kg",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abf94509-625e-447b-ace2-9f77a58f18ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.57,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "In June 2023, Fusion reported data from the first cold+hot dosing cohort at 15 kBq/kg:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6c65648-b428-4196-844d-eac70d01daf3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "Cohort 1 in Cold+Hot Dosing Regimen Showed Promising Results that Supported Dose Escalation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7738d402-e669-49e9-b8e3-98f70f20a1e9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 19,
      "from": 17,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "d2860898-6698-492a-878a-e8ba168bf1e1",
      "evidence": "The document presents results for the FPI-1434 Phase 1 Trial, including encouraging safety and early signals of antitumor activity",
      "position": 1,
      "objective": "Present promising results for FPI-1434 Phase 1 Trial",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}